Background: Non-radiographic axial spondyloarthritis is a progressive and disabling inflammatory disease affecting young adults, with limited treatment options. TNFi are more efficacious than JAKi and IL1-7i in nr-ax ...Background: Non-radiographic axial spondyloarthritis is a progressive and disabling inflammatory disease affecting young adults, with limited treatment options. TNFi are more efficacious than JAKi and IL1-7i in nr-ax SPA and it has a well-known safety profile over a longer duration. Recently, many IL-17i and JAKi were approved for the treatment of nr-ax SPA;however, data comparing IL1-7i and JAKi in terms of efficacy and safety is lacking. This systematized review aimed to compare the existing efficacy and safety data of JAKi vs IL-17i in the treatment of patients with nr-ax SPA. Methods: A systematic literature search was performed using relevant keywords in many databases. According to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA, 2020), relevant articles were included and evaluated in this review. Efficacy and safety data were collected, analyzed and compared through week 52. The first check was done by the end of week 14 and week 16 for upadacitinib and IL-17i respectively. Results: Data from four RCTs evaluating upadacitinib, secukinumab, ixekizumab, and bimekizumab comprising 1425 patients were analyzed. Overall, a comparable efficacy and safety profile were observed across different treatment arms through week 52;however, non-significant variations were encountered in some outcome measures. The primary endpoint among these RCTs (ASAS40 response rate) was met and it was higher in patients treated with bimekizumab 160 mg sc Q 4 weeks in TNFi non responders (48%) and lowest in ixekizumab 80 mg sc Q 4 weeks treated patients, (35%) (p Conclusion: The above-mentioned three IL-17i and the only one JAKi demonstrated comparable safety and efficacy profiles with some minor variations. A head-to-head trial comparing the effectiveness and safety characteristics of JAKi vs IL-17i may be needed in patients with active nr-ax SpA.展开更多
以油菜叶片为研究对象,利用高光谱成像技术,成功建立了叶绿素相对值SPAD值的预测模型。共采集了160个油菜叶片样本在380~1030nm范围内的高光谱图像。选择500~900nm之间的平均光谱作为油菜叶片样本的光谱。利用蒙特卡罗最小二乘法（monte...以油菜叶片为研究对象,利用高光谱成像技术,成功建立了叶绿素相对值SPAD值的预测模型。共采集了160个油菜叶片样本在380~1030nm范围内的高光谱图像。选择500~900nm之间的平均光谱作为油菜叶片样本的光谱。利用蒙特卡罗最小二乘法（monte carlo partial least squares,MC-PLS）剔除了13个异常样本,基于剩余的147个样本光谱数据与SPAD测量值进行分析,采用了不同的方法建立了多种预测模型,包括：全光谱的偏最小二乘法（partial least squares,PLS）模型,连续投影算法（successive projections algorithm,SPA）选择特征波长的PLS预测模型,＂红边＂位置（λred）的简单经验估测模型,三种植被指数R710/R760,（R750-R705）/（R750-R705）和R860/（R550＊R708）分别建立的简单经验估测模型,以及基于这三种植被指数的PLS预测模型。建模结果显示,全光谱的PLS模型预测效果最为精确,其预测相关系数rp为0.833 9,预测均方根误差RMSEP为1.52。而使用SPA算法选出的8个特征波长所建立的PLS模型其预测结果可达到与全光谱的PLS模型非常接近的水平,而且在保证一定精度的条件下减少了大量运算,节省了运算时间,大幅提高了建模的速度。而基于红边位置和选择的三种植被指数而建立的简单经验估计模型其预测结果虽与基于全光谱的PLS预测模型有一定差距,但模型简单、运算量小,适合用于对精度要求不高的场合,对后续的便携仪器设备开发有一定的指导作用。展开更多
文摘Background: Non-radiographic axial spondyloarthritis is a progressive and disabling inflammatory disease affecting young adults, with limited treatment options. TNFi are more efficacious than JAKi and IL1-7i in nr-ax SPA and it has a well-known safety profile over a longer duration. Recently, many IL-17i and JAKi were approved for the treatment of nr-ax SPA;however, data comparing IL1-7i and JAKi in terms of efficacy and safety is lacking. This systematized review aimed to compare the existing efficacy and safety data of JAKi vs IL-17i in the treatment of patients with nr-ax SPA. Methods: A systematic literature search was performed using relevant keywords in many databases. According to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA, 2020), relevant articles were included and evaluated in this review. Efficacy and safety data were collected, analyzed and compared through week 52. The first check was done by the end of week 14 and week 16 for upadacitinib and IL-17i respectively. Results: Data from four RCTs evaluating upadacitinib, secukinumab, ixekizumab, and bimekizumab comprising 1425 patients were analyzed. Overall, a comparable efficacy and safety profile were observed across different treatment arms through week 52;however, non-significant variations were encountered in some outcome measures. The primary endpoint among these RCTs (ASAS40 response rate) was met and it was higher in patients treated with bimekizumab 160 mg sc Q 4 weeks in TNFi non responders (48%) and lowest in ixekizumab 80 mg sc Q 4 weeks treated patients, (35%) (p Conclusion: The above-mentioned three IL-17i and the only one JAKi demonstrated comparable safety and efficacy profiles with some minor variations. A head-to-head trial comparing the effectiveness and safety characteristics of JAKi vs IL-17i may be needed in patients with active nr-ax SpA.
文摘以油菜叶片为研究对象,利用高光谱成像技术,成功建立了叶绿素相对值SPAD值的预测模型。共采集了160个油菜叶片样本在380~1030nm范围内的高光谱图像。选择500~900nm之间的平均光谱作为油菜叶片样本的光谱。利用蒙特卡罗最小二乘法（monte carlo partial least squares,MC-PLS）剔除了13个异常样本,基于剩余的147个样本光谱数据与SPAD测量值进行分析,采用了不同的方法建立了多种预测模型,包括：全光谱的偏最小二乘法（partial least squares,PLS）模型,连续投影算法（successive projections algorithm,SPA）选择特征波长的PLS预测模型,＂红边＂位置（λred）的简单经验估测模型,三种植被指数R710/R760,（R750-R705）/（R750-R705）和R860/（R550＊R708）分别建立的简单经验估测模型,以及基于这三种植被指数的PLS预测模型。建模结果显示,全光谱的PLS模型预测效果最为精确,其预测相关系数rp为0.833 9,预测均方根误差RMSEP为1.52。而使用SPA算法选出的8个特征波长所建立的PLS模型其预测结果可达到与全光谱的PLS模型非常接近的水平,而且在保证一定精度的条件下减少了大量运算,节省了运算时间,大幅提高了建模的速度。而基于红边位置和选择的三种植被指数而建立的简单经验估计模型其预测结果虽与基于全光谱的PLS预测模型有一定差距,但模型简单、运算量小,适合用于对精度要求不高的场合,对后续的便携仪器设备开发有一定的指导作用。
